The induction of G2/M cell-cycle arrest and apoptosis by cucurbitacin E is associated with increased phosphorylation of eIF2alpha in leukemia cells

Anticancer Drugs. 2010 Apr;21(4):389-400. doi: 10.1097/CAD.0b013e328336b383.

Abstract

The antiproliferative and apoptotic effects of cucurbitacin E, a natural product isolated from Cucurbitaceae, were determined in human leukemia HL-60 cells. Cucurbitacin E at low concentrations (3-50 nmol/l) inhibited the growth of HL-60 cells, which was associated with G2/M cell-cycle arrest, decrease in the levels of cyclin-dependent kinase1, and increase in the levels of p21. Cucurbitacin E at high concentrations (1-10 mol/l) induced apoptosis of HL-60 cells and activation of caspase-3, caspase-8, and caspase-9. Jurkat leukemia cells with or without caspase-8 expression were nearly equally sensitive to cucurbitacin E-induced apoptosis. Cucurbitacin E did not increase the levels of reactive oxygen species and antioxidants, N-acetylcysteine and catalase, did not block cucurbitacin E-induced apoptosis. Cucurbitacin E decreased the levels of the antiapoptotic proteins XIAP, survivin, and Mcl-1, but increased the level of the proapoptotic protein, Bax. The levels of phosphorylated eukaryotic translation initiation factor 2 subunit (eIF2) were induced in cells undergoing both apoptosis and cell-cycle arrest. As phosphorylated eIF2 is an inhibitor of protein translation initiation, our data suggest that cucurbitacin E induces cell growth arrest and apoptosis through the induction of eIF2 phosphorylation, which leads to the inhibition of cyclin-dependent kinase 1, Mcl-1, survivin, and/or XIAP protein synthesis and that cucurbitacin E induces apoptosis mainly through a mitochondrial-mediated pathway.

MeSH terms

  • Acetylcysteine / metabolism
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects*
  • CASP8 and FADD-Like Apoptosis Regulating Protein / metabolism
  • Caspase 3 / metabolism
  • Caspase 8 / metabolism
  • Caspase 9 / metabolism
  • Catalase / metabolism
  • Cell Cycle / drug effects*
  • Cell Division / drug effects
  • Eukaryotic Initiation Factor-2 / drug effects
  • Eukaryotic Initiation Factor-2 / metabolism*
  • G2 Phase / drug effects
  • Growth Inhibitors / pharmacology
  • Growth Inhibitors / therapeutic use
  • Humans
  • Inhibitor of Apoptosis Proteins
  • Jurkat Cells
  • Leukemia / drug therapy*
  • Leukemia / metabolism
  • Microtubule-Associated Proteins / metabolism
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Reactive Oxygen Species / metabolism
  • Survivin
  • Triterpenes / pharmacology*
  • Triterpenes / therapeutic use
  • X-Linked Inhibitor of Apoptosis Protein / metabolism

Substances

  • Antineoplastic Agents
  • BIRC5 protein, human
  • CASP8 and FADD-Like Apoptosis Regulating Protein
  • CFLAR protein, human
  • Eukaryotic Initiation Factor-2
  • Growth Inhibitors
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Proto-Oncogene Proteins c-bcl-2
  • Reactive Oxygen Species
  • Survivin
  • Triterpenes
  • X-Linked Inhibitor of Apoptosis Protein
  • Catalase
  • Caspase 3
  • Caspase 8
  • Caspase 9
  • cucurbitacin E
  • Acetylcysteine